AIDS Myelopathy: Proof of concept for the therapeutical concept is reached

12-Dec-2003
GENOPIA Biomedical GmbH announced today that a descriptive analysis of the data deriving from its clinical trial Phase II with patients suffering from AIDS Myelopathy resulted in a proof of concept for GENOPIA's strategy to treat these neurological dysfunctions. "Our compound is safe and well-tolerated in high doses without any evidence of toxicity." said Dr. Markus Weissbach, CMO of GENOPIA, "the efficacy results confirm our therapeutic concept and are an encouraging basis to perform a confirmatory follow up study. Lessons learned from the results of this study are a sufficiently long treatment period and a clearly defined patient population which should be considered when the effect of the compound is further evaluated. We are convinced that the upcoming phase III study will enable us to launch the first and only drug to treat AIDS Myelopathy in near future."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances